Yesterday Abbott Lab shares were up in the wall street as it had finally closed the deal to acquire Solvey Pharamaceutical (Belgium) for a whopping $6.6 billion deal, Abbott with this deal will acquire Solvay’s cholesterol drugs (Trilipix and Tricor) Market analyst report that Abbott will raise its sales to $3 billion in this particular portfolio by this coming year, Last quarter what we missed is that Abbott also went to acquire two medical devices companies one is Evalve Inc which is into cardiac valve development, deal size $410 Million and then Visiogen Inc (Eye treatment)- deal size $440 Million......first quarter of this year it also went to close a deal worth $2.2 billion when is acquired Advance medical optic (lens maker).....the thing to observe is these new innovation companies which Abbott went into acquire this year....will they help in to sustain its brand image and be the market leader which it has been in medical devices area for so long?
No comments:
Post a Comment